Etifoxine hydrochloride( HOE 36-801 hydrochloride )

Catalog No. M22932 CAS No. 56776-32-0

Etifoxine is an anxiolytic and anticonvulsant drug.?Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to β2 and β3 subunits of the GABAA receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	31	In Stock
5MG	50	In Stock
10MG	72	In Stock
25MG	138	In Stock
50MG	250	In Stock
100MG	444	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Etifoxine hydrochloride
Note

Research use only, not for human use.
Brief Description

Etifoxine is an anxiolytic and anticonvulsant drug.?Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to β2 and β3 subunits of the GABAA receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines.
Description

Etifoxine is an anxiolytic and anticonvulsant drug.?Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to β2 and β3 subunits of the GABAA receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines.(In Vitro):Etifoxine (EFX), at concentrations ranging from 10 to 300 μM (higher concentrations limited its solubility), produces a dose-dependent increase in the [3H]muscimol binding at equilibrium, to 155±2% of its control value at 300 μM EFX.(In Vivo):Etifoxine competitively inhibits [35S]TBPS binding with micromolar potency in rat brain.Etifoxine (3.125-50 mg/kg) exhibits more pronounced anxiolytic and anticonvulsant effects in the BALB/cByJ mice compared to the C57BL/6J mice.
In Vitro

Etifoxine (EFX), at concentrations ranging from 10 to 300 μM (higher concentrations limited its solubility), produces a dose-dependent increase in the [3H]muscimol binding at equilibrium, to 155±2% of its control value at 300 μM EFX.
In Vivo

Etifoxine competitively inhibits [35S]TBPS binding with micromolar potency in rat brain.Etifoxine (3.125-50 mg/kg) exhibits more pronounced anxiolytic and anticonvulsant effects in the BALB/cByJ mice compared to the C57BL/6J mice. Animal Model:Six-week old BALB/cByJ and C57BL/6J mice (20-25 g).Dosage:3.125-50 mg/kg.Administration:Intraperitoneal inhection.Result:Significantly increased the amount of time spent on the open arms at the 12.5 mg/kg dose when compared to vehicle (p = 0.009) in BALB/cByJ mice but produced no effect in C57B/6J mice.BALB/cByJ mice compared with C57BL/6J mice exhibited significantly (p < 0.012) lower plasma levels of the compound at 15 and 30 min.
Synonyms

HOE 36-801 hydrochloride
Pathway

Others
Target

Other Targets
Recptor

GABA
Research Area

——
Indication

——

Chemical Information

CAS Number

56776-32-0
Formula Weight

337.24
Molecular Formula

C17H18Cl2N2O
Purity

>98% (HPLC)
Solubility

DMSO:50 mg/mL (148.26 mM; Need ultrasonic)
SMILES

ClC1=CC=C2C(C(C3=CC=CC=C3)(C)OC(NCC)=N2)=C1.Cl
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Verleye M, Dumas S, Heulard I, et al. Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to overexpression of central GABAA receptor beta2 subunits? Eur Neuropsychopharmacol. 2011 Jun;21(6):457-70.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks